Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer

Human epidermal growth factor receptor type 2 (HER2) is overexpressed in various cancers; thus, HER2-targeting single-domain antibodies (sdAb) could offer a useful platform for radioimmunotherapy. In this study, we optimized the labeling of an anti-HER2-sdAb with the α-particle-emitter (225)Ac throu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodak, Magdalena, Dekempeneer, Yana, Wojewódzka, Maria, Caveliers, Vicky, Covens, Peter, Miller, Brian W., Sevenois, Matthijs B., Bruchertseifer, Frank, Morgenstern, Alfred, Lahoutte, Tony, D'Huyvetter, Matthias, Pruszyński, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716241/
https://www.ncbi.nlm.nih.gov/pubmed/36129807
http://dx.doi.org/10.1158/1535-7163.MCT-21-1021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716241/
https://www.ncbi.nlm.nih.gov/pubmed/36129807
http://dx.doi.org/10.1158/1535-7163.MCT-21-1021

Ejemplares similares